PMID- 32129112
OWN - NLM
STAT- MEDLINE
DCOM- 20210107
LR  - 20210107
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 19
IP  - 4
DP  - 2020 Apr
TI  - A safety evaluation of dimethyl fumarate in moderate-to-severe psoriasis.
PG  - 373-380
LID - 10.1080/14740338.2020.1736553 [doi]
AB  - Introduction: Psoriasis is a chronic inflammatory disorder affecting skin, nails 
      and joints. Systemic therapy of psoriasis is based upon several drugs which 
      include fumaric acid esters (FAEs), initially introduced in 1959. Since 2017, one 
      of the key substances among FAE spectrum (dimethyl fumarate; DMF) was registered 
      by the European Medicines Agency (EMA) for the treatment of moderate-to-severe 
      psoriasis vulgaris.Areas covered: This article covers the basic concepts 
      underlying usefulness of DMF in psoriasis and extensively reviews the studies, 
      which included its use in monotherapy of this dermatosis, with a particular 
      emphasis on safety aspects and adverse events (AEs).Expert opinion: DMF 
      monotherapy is a valuable systemic modality in the management of 
      moderate-to-severe psoriasis as proved by a recent phase III study. AEs 
      associated with DMF therapy are frequent, usually of mild severity, with a 
      dose-independent manner. Occasionally they are burdensome and require drug 
      discontinuation. The most common AEs comprise gastrointestinal symptoms, flushing 
      and white blood cell count abnormalities. The latter require strict monitoring to 
      prevent serious complications. Acknowledging the possibility of AEs, the use of 
      DMF in moderate-to-severe psoriasis is encouraged while the need of further 
      studies still remains.
FAU - Reszke, Radomir
AU  - Reszke R
AD  - Department of Dermatology, Venereology and Allergology, Wroclaw Medical 
      University, Wroclaw, Poland.
FAU - Szepietowski, Jacek C
AU  - Szepietowski JC
AD  - Department of Dermatology, Venereology and Allergology, Wroclaw Medical 
      University, Wroclaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20200311
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Dermatologic Agents)
RN  - FO2303MNI2 (Dimethyl Fumarate)
SB  - IM
MH  - Dermatologic Agents/administration & dosage/*adverse effects
MH  - Dimethyl Fumarate/administration & dosage/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Psoriasis/*drug therapy/pathology
MH  - Severity of Illness Index
OTO - NOTNLM
OT  - Dimethyl fumarate
OT  - adverse events
OT  - psoriasis
OT  - safety
EDAT- 2020/03/05 06:00
MHDA- 2021/01/08 06:00
CRDT- 2020/03/05 06:00
PHST- 2020/03/05 06:00 [pubmed]
PHST- 2021/01/08 06:00 [medline]
PHST- 2020/03/05 06:00 [entrez]
AID - 10.1080/14740338.2020.1736553 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2020 Apr;19(4):373-380. doi: 10.1080/14740338.2020.1736553. 
      Epub 2020 Mar 11.